News

FDA approves selexipag for pulmonary arterial hypertension


 

References

Selexipag has been approved to treat pulmonary arterial hypertension, the Food and Drug Administration announced on Dec. 21 in a statement.

“The FDA supports continued efforts to provide new treatment options for rare diseases,” Dr. Ellis Unger, director of the Office of Drug Evaluation I in the FDA’s Center for Drug Evaluation and Research, said in the statement. Selexipag (Uptravi) was granted orphan drug designation, which provides incentives such as tax credits, user fee waivers, and eligibility for exclusivity to assist and encourage the development of drugs for rare diseases.

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

Selexipag is an oral IP prostacyclin receptor agonist that dilates blood vessels, decreasing elevated pressure in pulmonary vessels.

In a trial of 1,156 patients with PAH, selexipag use for a median duration of 1.4 years was associated with fewer hospitalizations for PAH and a lower risk of disease progression, compared with placebo.

Common side effects observed in those treated with selexipag in the trial include headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in an extremity, and flushing.

Uptravi is marketed by San Francisco–based Actelion Pharmaceuticals US.

mdales@frontlinemedcom.com

On Twitter @maryjodales

Recommended Reading

Flu vaccines highly effective for pregnant women and their children
MDedge Family Medicine
‘Moderate’ flu activity seen in two U.S. states
MDedge Family Medicine
AHA: COPD doubles sudden cardiac death risk in hypertensives
MDedge Family Medicine
Tularemia outbreak in four U.S. states
MDedge Family Medicine
Pneumococcal serotypes likely to cause invasive disease dropped after PCV13 introduced
MDedge Family Medicine
Reslizumab: FDA panel recommends approval for adults, but not children
MDedge Family Medicine
Self-reported poor functional status predicts perioperative morbidity
MDedge Family Medicine
Measures that don’t account for DNR status could unfairly penalize hospitals
MDedge Family Medicine
Early infection-related hospitalization portends poor breast cancer prognosis
MDedge Family Medicine
Men seen as main source of TB transmission
MDedge Family Medicine